Clinical screening of epipodophyllotoxin VM26 in malignant lymphomas and solid tumours.
Epipodophyllotoxin (VM 26; 4'-demethyl-epipodophyllotoxin-beta-D-thenylidene glucoside) has been proved, in clinical screening, to be able to induce apparently complete remissions and pronounced though incomplete regressions in Hodgkin's disease, reticulosarcoma, and bladder cancer, as well as incomplete regressions in lymphosarcoma. Apparently complete regressions of malignant pleural effusions have been obtained after giving this drug systemically. It has a notable toxic action on the bone marrow.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000505:Alopecia / Q000139:chemically induced; D000741:Anemia, Aplastic / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001791:Blood Platelet Disorders / Q000139:chemically induced; D002648:Child; D002986:Clinical Trials as Topic; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006027:Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006410:Hematopoiesis / Q000187:drug effects; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D007783:Lactones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy*; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis / Q000188:drug therapy; D009369:Neoplasms / Q000188:drug therapy*; D010946:Plants, Medicinal; D010947:Plants, Toxic; D011035:Podophyllum; D012075:Remission, Spontaneous; D013876:Thiophenes / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents; D006027:Glycosides; D007783:Lactones; D013876:Thiophenes